In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis

Marta Martins; Zsuzsanna Schelz; Ana Martins; Joseph Molnar; Gyorgy Hajös; Zsuzsanna Riedl; Miguel Viveiros; Ismail Yalcin; Esin Aki-Sener; Leonard Amaral

doi:10.1016/j.ijantimicag.2006.10.013

In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis

Marta Martins, Zsuzsanna Schelz, Ana Martins, Joseph Molnar, Gyorgy Hajös, Zsuzsanna Riedl, Miguel Viveiros, Ismail Yalcin, Esin Aki-Sener, Leonard Amaral

Research output: Contribution to journal › Article › peer-review

66 Citations (Scopus)

Abstract

Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB). Because current therapy of MDRTB is highly problematic even when all five 'first line of defence' drugs are employed, there is a need for effective antituberculosis drugs. New derivatives of TZ were synthesised and their in vitro activity against a reference strain of M. tuberculosis was evaluated with the aid of the BACTEC 460 system. Derivatives that presented significant activity were evaluated by ex vivo studies and were shown to enhance the killing of intracellular M. tuberculosis.

Original language	English
Pages (from-to)	338-340
Number of pages	3
Journal	International Journal Of Antimicrobial Agents
Volume	Vol. 29
Issue number	n.º 3
DOIs	https://doi.org/10.1016/j.ijantimicag.2006.10.013
Publication status	Published - Mar 2007

Keywords

Derivatives
Ex vivo activity
In vitro activity
Multidrug resistance
Mycobacterium tuberculosis
Thioridazine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijantimicag.2006.10.013

Cite this

@article{36ef5d8afb804824aed5b6a9f13006f9,

title = "In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis",

abstract = "Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB). Because current therapy of MDRTB is highly problematic even when all five 'first line of defence' drugs are employed, there is a need for effective antituberculosis drugs. New derivatives of TZ were synthesised and their in vitro activity against a reference strain of M. tuberculosis was evaluated with the aid of the BACTEC 460 system. Derivatives that presented significant activity were evaluated by ex vivo studies and were shown to enhance the killing of intracellular M. tuberculosis.",

keywords = "Derivatives, Ex vivo activity, In vitro activity, Multidrug resistance, Mycobacterium tuberculosis, Thioridazine",

author = "Marta Martins and Zsuzsanna Schelz and Ana Martins and Joseph Molnar and Gyorgy Haj{\"o}s and Zsuzsanna Riedl and Miguel Viveiros and Ismail Yalcin and Esin Aki-Sener and Leonard Amaral",

year = "2007",

month = mar,

doi = "10.1016/j.ijantimicag.2006.10.013",

language = "English",

volume = "Vol. 29",

pages = "338--340",

journal = "International Journal Of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "n.º 3",

}

TY - JOUR

T1 - In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis

AU - Martins, Marta

AU - Schelz, Zsuzsanna

AU - Martins, Ana

AU - Molnar, Joseph

AU - Hajös, Gyorgy

AU - Riedl, Zsuzsanna

AU - Viveiros, Miguel

AU - Yalcin, Ismail

AU - Aki-Sener, Esin

AU - Amaral, Leonard

PY - 2007/3

Y1 - 2007/3

N2 - Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB). Because current therapy of MDRTB is highly problematic even when all five 'first line of defence' drugs are employed, there is a need for effective antituberculosis drugs. New derivatives of TZ were synthesised and their in vitro activity against a reference strain of M. tuberculosis was evaluated with the aid of the BACTEC 460 system. Derivatives that presented significant activity were evaluated by ex vivo studies and were shown to enhance the killing of intracellular M. tuberculosis.

AB - Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB). Because current therapy of MDRTB is highly problematic even when all five 'first line of defence' drugs are employed, there is a need for effective antituberculosis drugs. New derivatives of TZ were synthesised and their in vitro activity against a reference strain of M. tuberculosis was evaluated with the aid of the BACTEC 460 system. Derivatives that presented significant activity were evaluated by ex vivo studies and were shown to enhance the killing of intracellular M. tuberculosis.

KW - Derivatives

KW - Ex vivo activity

KW - In vitro activity

KW - Multidrug resistance

KW - Mycobacterium tuberculosis

KW - Thioridazine

UR - http://www.scopus.com/inward/record.url?scp=33846969173&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/science/article/abs/pii/S0924857906004742?via%3Dihub

U2 - 10.1016/j.ijantimicag.2006.10.013

DO - 10.1016/j.ijantimicag.2006.10.013

M3 - Article

C2 - 17239569

AN - SCOPUS:33846969173

VL - Vol. 29

SP - 338

EP - 340

JO - International Journal Of Antimicrobial Agents

JF - International Journal Of Antimicrobial Agents

SN - 0924-8579

IS - n.º 3

ER -

In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this